Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2897 Target Snapshot

Dual specificity mitogen-activated protein kinase kinase 4 · SINGLE PROTEIN · Homo sapiens

726Compounds
250Assays
9Approved Drugs
570.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P45985. Use UniProt P45985 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P45985 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dual specificity mitogen-activated protein kinase kinase 4 as ChEMBL target CHEMBL2897, mapped to UniProt P45985. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dual specificity mitogen-activated protein kinase kinase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2897
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P45985
Dual specificity mitogen-activated protein kinase kinase 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dual specificity mitogen-activated protein kinase kinase 4 is the right protein anchor across sources, using UniProt P45985 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDual specificity mitogen-activated protein kinase kinase 4
UniProt AccessionP45985
Component TypeProtein
Sequence Length399 aa

Dual specificity mitogen-activated protein kinase kinase 4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Dual specificity mitogen-activated protein kinase kinase 4, mapped to UniProt P45985. Sequence length is 399 aa.

Mapped IDP45985
Review nameDual specificity mitogen-activated protein kinase kinase 4
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

9
Approved
3
Phase III
4
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50345.0
KD225.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4865410 8.82 Kd 1.5 Preclinical
CHEMBL4798975 8.77 Kd 1.7 Preclinical
CHEMBL603469 8.42 Kd 3.8 Clinical
CHEMBL4790247 7.54 IC50 29.0 Preclinical
CHEMBL4758063 7.39 IC50 41.0 Preclinical
CHEMBL6062934 7.22 IC50 60.0 Preclinical
CHEMBL4879048 7.21 IC50 61.0 Preclinical
CHEMBL5923880 7.2 IC50 63.0 Preclinical
CHEMBL388978 7.16 Kd 70.0 Preclinical
CHEMBL4866649 7.08 IC50 83.0 Preclinical
Distribution

pChEMBL Value Distribution

22
5.0
25
5.5
132
6.0
25
6.5
13
7.0
1
7.5
2
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TOVORAFENIB
CHEMBL3348923
Approved 2024
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

250
Total Assays
152
Tested Compounds
1
Assay Types
Binding — 250 assays, 152 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 156 108 6.2
cell-based format 37 39 5.9
assay format 32 2 8.8
subcellular format 25 3 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine